Conference Track

Prognosis and Prediction

Source: CCO Independent Conference Coverage of the CCO Independent Conference Coverage of the 2007 San Antonio Breast Cancer Symposium*

*CCO is an independent medical education company that provides state-of-the-art medical information to healthcare professionals through conference coverage and other educational programs.

Capsule Summaries

21-Gene Recurrence Score Assay Prognostic in Hormone Receptor–Positive, Operable Breast Cancer
70-Gene Profile Predicts Survival in Patients With Lymph Node-Positive Breast Cancer
Limited Predictive Value of Polysomy 17 in Patients With Breast Cancer Treated With Anthracycline-Based Chemotherapy and Trastuzumab
Recurrence Score Assay Predicts Adjuvant Therapy Benefit in Women With Node-Positive, ER-Positive Breast Cancer
Stroma Gene Signature Associated With Resistance to Neoadjuvant Anthracycline Therapy in Patients With Operable and Locally Advanced ER-Negative Breast Cancer
Anthracycline Benefit Observed Only With Topoisomerase IIa Amplification in Patients With HER2-Positive Breast Cancer
CYP2D6*2A Polymorphism Associated With Increased Response to Tamoxifen and Decreased Incidence of Breast Cancer
Combination of 81-Gene Copy Number Alteration Signature and Gene Expression Signature Predictive of Chemotherapy Response
PCR-Based Assay Shows Greater Sensitivity Compared With Frozen-Section Histology for Detecting Difficult-to-Detect Lymph Node Metastases
6-Factor Model Predictive of Risk of Relapse in Stage II/III ER–Positive Breast Cancer
Ki-67 May Be Useful as Prognostic Marker in Postmenopausal Patients With ER-Positive Breast Cancer Treated With Adjuvant Endocrine Therapy
DFS Benefit of Adjuvant Trastuzumab in HER2-Positive Breast Cancer Independent of HER2 Assessment Method, Ratio, or Gene Copy Number

Expert Analysis

Expert Analysis: Prognosis and Prediction

Faculty:

Matthew Ellis, MD, PhD
Daniel F. Hayes, MD
Hope S. Rugo, MD

Learning Objectives

Upon completion of this activity, participants should be able to:

Discuss the use of genetic signatures in determining benefit from therapy for patients with breast cancer
Cite the significance of genetic polymorphisms on metabolism of therapeutic agents used in the treatment of breast cancer
Describe prognostic markers used to predict outcomes in patients with breast cancer

CREDIT INFORMATION

Release Date: 02/21/08

Expiration Date: 02/20/09

Physicians: maximum of 1.25 AMA PRA Category 1 Credits™

Registered Nurses: 1.3 Nursing contact hours

Pharmacists: 1.3 contact hours (0.13 CEUs)

Status: Please log in to view status

Disclaimer: The materials published on the Clinical Care Options Web site reflect the views of the reviewers or authors of the CCO material, not those of Clinical Care Options, LLC, the CME provider, or the companies providing educational grants. The materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or using any therapies described in these materials.